Esperion presents positive Phase 3 NEXLETOL data

Esperion Therapeutics Logo

Esperion (NASDAQ: ESPR) presented positive pooled results from four Phase 3 NEXLETOL trials at the virtual American Heart Association scientific sessions.

NEXLETOL, or bempedoic acid, is a non-statin, low-density lipoprotein cholesterol (LDL-C)-lowering drug that was approved by the FDA earlier this year for the treatment of atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. 

The first analysis demonstrated that a subgroup of more than 580 patients who cannot tolerate statins showed a 26.5% reduction of in LDL-C when taking NEXLETOL, compared with those taking placebo, by week 12.

The second analysis showed that, in a pooled population of more than 3,600 patients, NEXLETOL significantly lowered LDL-C at week 12, compared with placebo. LDL-C lowering was numerically greater in females than in males across both study pools, in both statin-intolerant patients and those receiving background maximally tolerated statins.

“Women are half of the population, and nearly 10-million patients in the U.S. with high LDL-C levels are not on statins due to tolerability issues, yet these groups have been underrepresented in previous medical research,” Ashley Hall, Esperion’s chief development officer, said in a statement.

“Our goal at Esperion is lipid management for everybody, and these analyses show significant LDL-C efficacy and acceptable safety for NEXLETOL in these subgroups,” she added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.